Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114539 | 1.00 | LCK (0.52) | LCKRAB9APDPK1DYRK1AKMT2A | |
| SCHEMBL31114561 | 0.88 | LCK (0.50) | LCKRAB9ADYRK1A | |
| SCHEMBL25260578 | 0.88 | LCK (0.50) | LCKRAB9ADYRK1A | |
| SCHEMBL30450130 | 0.88 | LCK (0.42) | LCKPDPK1DYRK1AKMT2AP2RX3 | |
| SCHEMBL31114518 | 0.87 | LCK (0.53) | LCKRAB9ADYRK1AKMT2AKDM4E | |
| SCHEMBL25259071 | 0.87 | LCK (0.53) | LCKRAB9ADYRK1AKMT2AKDM4E | |
| SCHEMBL30450911 | 0.83 | LCK (0.46) | LCKRAB9ADYRK1A | |
| SCHEMBL25305115 | 0.83 | LCK (0.51) | LCKRAB9APDPK1DYRK1AKMT2A | |
| SCHEMBL31114499 | 0.83 | LCK (0.56) | LCKRAB9APDPK1DYRK1AKMT2A | |
| SCHEMBL25303576 | 0.83 | LCK (0.56) | LCKRAB9APDPK1DYRK1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INST NAT SANTE RECH MED (FR) | 2025-12-18 | — | — | US | disclosed |
| EP-4460500-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023131649-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131649-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | BBOX1, NDUFB6, NDUFB5 | LCK 1173/4885RAB9A 2727/4885PDPK1 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.